Clinical implications of urokinase and tissue type plasminogen activators and their inhibitor (PAI-1) in breast cancer tissue

Oncology Reports

Volumn 9, Issue 3, 2002, Pages 645-651

  Luqmani, Y A ^a,b   Temmim, L ^b   Parkar, A H ^b   Mathew, M ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b KUWAIT CANCER CONTROL CENTER   (Kuwait)

Author keywords

Breast cancer; PAI 1; Plasminogen activators; Prognostic indicators; Survival; tPA; uPA

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; PROTEIN; TFF1 PROTEIN, HUMAN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR SUPPRESSOR PROTEIN; UROKINASE;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BLOOD; BREAST TUMOR; CYTOSOL; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PROGNOSIS; PROTEIN SYNTHESIS; TIME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOSOL; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; PROTEIN BIOSYNTHESIS; PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TUMOR SUPPRESSOR PROTEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036585006     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.3.645     Document Type: Article

References (44)

1. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991. (Pubitemid 121001258)
2. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen PI, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266, 1985.
3. Rochefort H, Capony F and Garcia M: Cathepsin D: a protease involved in breast cancer metastasis. Cancer Metastases Rev 9: 321-331, 1990.
4. Brunner N, Holst-Hansen C, Pedersen AN, Pyke C, Hoyer-Hansen G, Foekens J and Stephens RW: Urokinase plasminogen activator receptor in breast cancer. Breast cancer: advances in biology and therapeutics. Calvo F, Crepin M and Magdelenat H (eds). John Libbey Eurotext, pp201-220, 1996.
5. Hekman CM and Loskutoff DJ: Fibrinolytic pathways and the endothelium. Semin Thromb Hemost 13: 514-527, 1987. (Pubitemid 18007754)
6. Duffy MJ: Urokinase type plasminogen activator and malignancy. Fibrinolysis 7: 295-302, 1993.
7. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618, 1996.
8. Janicke F, Schmitt M and Graeff H: Clinical relevance of the urokinase type and tissue type plasminogen activators and of their type 1 inhibitor in breast cancer. Sem Throm Hem 17: 303-312, 1991.
9. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen HJ: Urokinase plasminogen activator, a marker for aggressive breast cancers. Cancer 62: 531-533, 1988.
10. Duffy MJ: Plasminogen activators and cancer. Blood Coagul Fibrinolysis 1:681-687, 1990.
11. Janicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gossner W and Graeff H: Urokinase type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78, 1990. (Pubitemid 20270731)
12. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontelbal M, Janicke F and Klijn JGM: Prognostic value of urokinase type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992.
13. Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Pous M, Deytieux Le Doussal V, Tubiana-Hulin M and Brunet M: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266-1272, 1992.
14. Grondahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Papot H, Ronne E, Dano K and Blichert-Toft M: High levels of urokinase type plasminogen activator and it's inhibitor PAI-1 in cytoslic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993. (Pubitemid 23168015)
15. Ferno M, Dendahl PO, Borg A, Brundell J, Hirschberg L, Olsson H and Killander D: Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 32A: 793-801, 1996.
16. Peyrat JP, Vanlemmens L, Foumier J, Huet G, Revillion F and Bonneterre J: Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers. Clin Cancer Res 4: 189-196, 1998. (Pubitemid 28062895)
17. Janicke F, Schmitt M, Pache L, Ulm K, Hofler H and Graeff H: Urokinase plasminogen activator (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res Treat 24: 195-208, 1993. (Pubitemid 23062819)
18. Stephens RW, Brunner N, Janicke F and Schmitt M: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 52: 99-111, 1998. (Pubitemid 29056088)
19. Duffy MJ, Maguire TM, McDermott EW and O'Higgins N: Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71: 130-135, 1999. (Pubitemid 29288493)
20. Look MP: Pooled analysis of uPA and PAI-1 for prognosis in primary breast cancer patients. EORTC Receptor and Biomarker Study Group. Int J Biol Markers 15: 70-72, 2000.
21. Hildenbrand R, Dilger I, Horlin A and Stutte HJ: Urokinase and macrophages in tumour angiogenesis. Br J Cancer 72: 818-823, 1995.
22. Yamashita J, Ogawa M, Yamashita S, Nakashima Y, Saishoji T, Nomura K, Inada K and Kawano I: Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br J Cancer 68: 524-529, 1993. (Pubitemid 23258456)
23. De Bruin PAF, Griffioen G, Verspaget HW, Verheijen JH, Dooijewaard G, van den Ingh HF and Lamers CBHW: Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res 48: 4520-4524, 1982.
24. Hoylerts M, Dingeman CR, Lijnen HR and Coilen D: Kinetics of the activation of plasminogen by human tissue plasminogen activator. J Biol Chem 257: 2912-2919, 1982. (Pubitemid 12118804)
25. Sumiyoshi K, Baba S, Sakaguchi S, et al: Increase in levels of plasminogen activator and type 1 plasminogen activator inhibitor in human breast cancer: possible roles in tumour progression and metastasis. Thromb Res 63: 59-71, 1991.
26. Reilly D, Christensen L and Duch M, et al: Type 1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 50: 208-214, 1992.
27. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL and Klijn JG: The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60: 636-643, 2000. (Pubitemid 30094561)
28. Knoop A, Andreasen PA, Andersen JA, Hansen S, Laenkholm AV, Simonsen ACW, Andersen J, Overgaard J and Rose CL: Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 77: 932-940, 1998. (Pubitemid 28101782)
29. De Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, van Tienoven TH, Heuvel JJ, Bolt-De Vries J, Benraad TJ and Foekens JA: Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer 80: 286-294, 1999. (Pubitemid 29210120)
30. Harbeck N, Alt U, Berger U, Kates R, Kruger A, Thomssen C, Janicke F, Graeff H and Schmitt M: Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. Int J Biol Markers 15: 79-83, 2000. (Pubitemid 30195489)
31. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Hofler H, Janicke F and Graeff H: Time varying prognostic impact of tumour biological factors urokinase (uPA), PA1-I and steroid hormone receptor status in primary breast cancer. Br J Cancer 76:306-311, 1997. (Pubitemid 27308079)
32. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A and Oglobine J: Prognostic value of urokinase type plasminogen activator (uPA) and plasminogen activator inhibitors PA1-I and PA2-I in breast carcinomas. Br J Cancer 69: 398-405, 1994. (Pubitemid 24046572)
33. Foekens J A, Schmitt M, Peters HA, Look MP, van Putten WL, Kramer MD, Janicke F and Klijn JG: Association of PA1-I with metastasis-free survival in breast cancer: comparison with ER, PgR, pS2, cathepsin D and uPA. In: Prospectives in Diagnosis and Treatment of Breast Cancer. Schmidt M (ed). Excerpta Medica, Amsterdam, pp197-205, 1994.
34. Kute TE, Grondahl-Hansen J, Shao SM, Long R, Russell G and Brunner N: Low cathepsin D and low plasminogen activator type 1 inhibitor in tumour cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 47: 9-16, 1998. (Pubitemid 28048146)
35. Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Janicke F and Klijn JG: Plasminogen activator inhibitor 1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658, 1994. (Pubitemid 24245001)
36. Luqmani YA, Temmim L, Memon A, Ali MA and Parkar AH: Steroid receptor measurement in breast cancers: comparison between ligand binding and enzyme-immunoassay in cytosolic and nuclear extracts. Int J Cancer 71: 526-538, 1997. (Pubitemid 27239360)
37. Bloom HG and Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957.
38. Grebenschikov N, Guerts-Moespot A, de Witte H, Heuvel J, Leake R, Sweep F and Benraad T: A sensitive and robust assay for urokinase and tissue type plasminogen activators (uPA and tPA) and their inhibitor type 1 (PA1-I) in breast tumour cytosols. Int J Biol Markers 12: 6-14, 1997. (Pubitemid 27229450)
39. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1957.
40. Shiba E, Kim SJ, Taguchi T, Izukura M, Kobayashi T, Furukawa J, Yayoi E, Shin E, Takatsuka Y, Koyama H and Takai S: A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue. J Cancer Res Clin Oncol 123: 555-559, 1997. (Pubitemid 27483769)
41. Broet P, Spyratos F, Romain S, Quillien V, Daver A, Ricolleau G, Rallet A, Toulas C and Asselain B: Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study. Br J Cancer 80: 536-545, 1999. (Pubitemid 29213211)
42. Luqmani YA, Temmim L, Memon A, Parkar AH, Ali MA, Motawy M and Bakr H: Immunoradiometric measurement of pS2 in breast cancer. Acta Oncol 38: 805-814, 1999.
43. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The urokinase type plasminogen activator system in cancer metastases: a review. Int J Cancer 72: 1-22, 1997. (Pubitemid 27314632)
44. Powles T: Adjuvant therapy for early breast cancer: a time to refine. J Natl Cancer Inst 89: 1652-1654, 1997.